Stephen Wargacki - Mar 7, 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
Chief Science Officer
Signature
/s/ Lori Braender, as Attorney-In-Fact
Stock symbol
AQST
Transactions as of
Mar 7, 2025
Transactions value $
-$86,581
Form type
4
Date filed
3/11/2025, 05:49 PM
Previous filing
May 13, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Award $0 +115K +43.99% $0.00 376K Mar 7, 2025 Direct F1
transaction AQST Common Stock Tax liability -$34.1K -12.9K -3.42% $2.65 364K Mar 7, 2025 Direct F2
transaction AQST Common Stock Tax liability -$40.9K -15.4K -4.24% $2.65 348K Mar 9, 2025 Direct F2
transaction AQST Common Stock Tax liability -$11.6K -4.57K -1.31% $2.54 344K Mar 10, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AQST Non-Qualified Stock Option (right to buy) Award $0 +65K $0.00 65K Mar 7, 2025 Common Stock 65K $2.65 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
F2 Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.
F3 The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.